Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LUPIN.NS
Strong BuyFull HouseLupin Limited · Healthcare · India · $10.2B · Avg Vol: $22M/d
91
StockRankGet insider-trade alerts
Q
81
V
56
M
55
P/E (TTM)
17.4x
ROE
23.8%
D/E
0.3x
Dividend %
0.9%
COMPANY DESCRIPTION
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 162.7B | 196.6B | 221.9B | 274.9B | 19.1% | 300.7B | 297.8B | 317.5B | 7.5% |
| EPS (INR) | 9.46 | 42.05 | 71.95 | 116.75 | 131.1% | 121.22 | 87.56 | 93.18 | -10.7% |
| Shares | 455.0M | 455.7M | 456.6M | 457.2M | +0.5% | 457.3M | — | — | — |
| Debt | 45.4B | 29.2B | 54.5B | 66.2B | 13.4% | 66.4B | — | — | — |
| Equity | 124.6B | 142.9B | 172.0B | 224.5B | 21.7% | — | — | — | — |
| Op CF | 19.0B | 36.5B | 30.0B | 73.3B | 56.9% | 73.6B | — | — | — |
| Inv CF | -12.9B | -17.1B | -41.7B | -38.6B | — | — | — | — | — |
| Fin CF | -3.4B | -21.8B | 17.3B | -8.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-13.3%
SMA 50SMA 200
Close
$22.01
RSI (14)
22.7
52W High
$26.45
From 52W High
0.8%
SCORE BREAKDOWN
Quality
81
ROIC
28.3%95.8
ROE
23.8%91.8
GP/Assets
56.5%89.8
Op. Margin
25.4%88.6
FCF/Assets
13.8%92.2
Piotroski
783.9
Int. Cover
17.7x70.0
D/E Ratio
0.29x41.4
Current Ratio
1.90x36.6
Value
56
P/E (TTM)
17.4x66.7
EV/EBITDA
11.0x65.0
P/FCF
18.3x65.8
P/B
4.3x34.0
P/S
3.2x54.9
Div Yield
0.9%25.1
Momentum
55
52W High %
83%72.6
RS 6M
-6%58.5
SMA 50/200
1.03x64.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-15%15.9
Q Growth
16%51.9
FUNDAMENTALS
Market Cap
$10.2B
P/E (Forward)
20.5x
Gross Margin
72.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LUPIN.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LUPIN.NS | Lupin Limited(you) | $10.2B | 91 | Strong Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| GLENMARK.NS | Glenmark Pharmaceuticals Limited | $7.4B | 94 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%